tretinoin has been researched along with Kidney-Failure--Chronic* in 13 studies
1 review(s) available for tretinoin and Kidney-Failure--Chronic
1 trial(s) available for tretinoin and Kidney-Failure--Chronic
12 other study(ies) available for tretinoin and Kidney-Failure--Chronic
Article | Year |
---|---|
Survival of Patients on Hemodialysis and Predictors of Mortality: a Single-Centre Analysis of Time-Dependent Factors.
This study aimed to evaluate the outcome and predictors of survival in hemodialysis patients of Hasheminejad Kidney Center where a comprehensive dialysis care program has been placed since 2004.. Data of 560 hemodialysis patients were used to evaluate 9-year survival rates and predictors of mortality. Cox regression models included comorbidities as well as averaged and 6-month-averaged time-dependent values of laboratory findings as independent factors.. Survival rates were 91.9%, 66.0%, 46.3%, and 28.5%, at 1, 3, 5, and 9 years, respectively, in all patients and 90.8%, 61.6%, 42.1%, and 28.0% in 395 incident patients starting hemodialysis after 2004. Adjusted survival models demonstrated age, male sex, diabetes mellitus, cardiovascular disease, and high-risk vascular access as baseline predictors of mortality, as well as averaged low hemoglobin level (hazard ratio [HR], 1.98; 95% confidence interval [CI], 1.36 to 2.90) and a single-pool KT/V < 1.2 (HR, 2.28; 95% CI, 1.60 to 3.26). The averaged high-density lipoprotein cholesterol (HR, 0.67; 95% CI, 0.55 to 0.81) and serum creatinine (HR, 0.71; 95% CI, 0.64 to 0.79) levels demonstrated protective effects. The adjusted time-dependent model further revealed the significant association of hypocalcemia (HR, 1.63; 95% CI, 1.13 to 2.34), hypercalcemia (HR, 1.50; 95% CI, 1.02 to 2.21), and hyperphosphatemia (HR, 1.68; 95% CI, 1.20 to 2.37) with death.. Our patients have relatively comparable survival rates with high-profile dialysis centers. Aiming to better achieve the recommended targets, especially hemoglobin and nutritional and bone metabolism factors, should be considered for optimal dialysis outcomes. Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Child; Cholesterol, HDL; Creatinine; Diabetes Mellitus; Female; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Infections; Iran; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Neoplasms; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Risk Factors; Sex Factors; Survival Rate; Time Factors; Tretinoin; Young Adult | 2016 |
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.
Acute promyelocytic leukemia (APL) has the best prognosis among acute leukemias, but there is little data about APL in patients on hemodialysis. A 64-year-old hemodialysis patient was successfully treated for APL by induction therapy with all-trans retinoic acid (ATRA), three courses of consolidation therapy with Ara-C, mitomycin C (MIT), daunorubicin (DNR), and idarubicin (IDR), and maintenance therapy with ATRA. Complete remission has been maintained for 42 months in this patient. With dose modification, ATRA and chemotherapy may be safely given to patients on hemodialysis. Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Middle Aged; Mitomycin; Remission Induction; Renal Dialysis; Tretinoin | 2011 |
Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney.
Although all-trans retinoic acid (ATRA) is widely used in acute promyelocytic leukemia (APL), there is little data as to whether or not ATRA is useful for patients with liver and renal failure. A 63-year-old APL patient, complicated by Child-Pugh class A liver cirrhosis and chronic renal failure (creatinine 3.2 mg/dL), was successfully treated with 45 mg/m(2)/day of ATRA. With three courses of chemotherapy, complete remission has been maintained for four years in this patient. Serum trough and maximum ATRA concentration, and the area under the curve (AUC) were not elevated. These observations suggest that full-dose ATRA therapy might be safely applicable to such a complicated case with APL. Topics: Antineoplastic Agents; Humans; Hypercalcemia; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Polycystic Kidney Diseases; Remission Induction; Tretinoin | 2009 |
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
Cardiovascular events are accelerated in chronic kidney disease (CKD). Although deranged nitric oxide (NO) pathways and asymmetric dimethylarginine (ADMA) cause endothelial dysfunction, no direct evidence for coronary artery endothelial dysfunction in CKD has been documented. CKD was induced in male dogs by heminephrectomy (1/2Nx) or five-sixths nephrectomy (5/6Nx). After 4 wk, renal ablation reduced GFR (control 76 [54 to 85]; 1/2Nx 38 [29 to 47]; 5/6Nx 15 [12 to 46] ml/min) and elevated plasma ADMA (control 1.88 [1.68 to 2.54]; 1/2Nx 2.51 [2.11 to 3.55]; 5/6Nx 3.84 [2.16 to 3.95] micromol/L). Coronary circulatory responses to acetylcholine revealed marked increases in coronary blood flow in control group (83 +/- 17% increment) but blunted responses in 1/2Nx (34 +/- 8% increment) and 5/6Nx (20 +/- 4% increment). The acetylcholine-induced changes in epicardial arteriolar diameter, using needle-lens probe charge-coupled device videomicroscopy, showed similar results. The responsiveness to sodium nitroprusside did not differ among three groups. Plasma nitrite/nitrate levels decreased in 1/2Nx and 5/6Nx, and the mRNA expressions of dimethylarginine dimethylaminohydrolase-II (DDAH-II), ADMA-degrading enzyme, and endothelial NO synthase (eNOS) in coronary arteries were downregulated in 1/2Nx and 5/6Nx. Finally, 4-wk treatment with all-trans retinoic acid restored the impaired endothelium-dependent vasodilation and reversed the expression of eNOS but not DDAH-II. Coronary endothelial function is impaired in the early stage of CKD. The dysfunction is attributed to the downregulation of eNOS and/or DDAH-II in coronary arteries. Furthermore, the manipulation of NO pathways may constitute a therapeutic strategy for the prevention of coronary dysfunction in CKD. Topics: Acetylcholine; Amidohydrolases; Animals; Arginine; Coronary Circulation; Disease Models, Animal; Dogs; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Glomerular Filtration Rate; Kidney Failure, Chronic; Male; Microscopy, Video; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Tretinoin; Vasodilation; Vasodilator Agents | 2007 |
ACE inhibitor use and the long-term risk of renal failure in diabetics.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Diabetes Mellitus; Diabetic Nephropathies; Disease Progression; Follow-Up Studies; Humans; Kidney Failure, Chronic; Proteinuria; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Tretinoin | 2006 |
Retinoic acid exacerbates experimental radiation nephropathy.
Studies have shown that angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker can delay, but cannot reverse, the progression of experimentally induced radiation nephropathy. In an effort to find a method for reversing injury, three agents were tested in a rat model of radiation nephropathy. Pirfenidone (a phenyl-pyridone antifibrotic) and thiaproline (an inhibitor of collagen deposition) were not capable of retarding the development of radiation nephropathy. However, all-trans retinoic acid (an anti-inflammatory agent) exacerbated radiation nephropathy. We speculated that the detrimental effects of retinoic acid might be the result of stimulation of renal cell proliferation. However, retinoic acid had no effect on tubular or glomerular cell proliferation in normal animals and did not enhance radiation-induced proliferation. A recent report that retinoic acids inhibit nitric oxide production suggested an alternative mechanism, since inhibition of production of nitric oxide is known to exacerbate radiation nephropathy. Experiments demonstrated that retinoic acid exacerbated the radiation-induced drop in renal production of nitric oxide, suggesting that the detrimental effect of all-trans retinoic acid might be explained by inhibition of renal nitric oxide activity. Particularly in view of the recent clinical report of enhancement of radiation nephropathy by retinoic acid in patients receiving bone marrow transplantation, the combination of retinoic acid and renal irradiation should be carried out with great caution. Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Extracellular Matrix; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Kidney Failure, Chronic; Proteinuria; Pyridones; Radiation Injuries, Experimental; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidines; Tretinoin; Uremia; Whole-Body Irradiation | 2002 |
Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis.
1. Plasma concentrations of acitretin and its metabolite (13-cis acitretin) were measured in six patients on haemodialysis and six subjects without renal failure following a single oral dose of 50 mg of acitretin. 2. The mean areas under the plasma concentration vs time curves of acitretin and its metabolite were about 50% lower in patients on haemodialysis. 3. No retinoids were detectable in the dialysate. Topics: Acitretin; Administration, Oral; Adult; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Tretinoin | 1989 |
Reactive perforating collagenosis of renal failure/diabetes responsive to topical retinoic acid.
Topics: Administration, Topical; Darier Disease; Diabetes Complications; Humans; Kidney Failure, Chronic; Male; Middle Aged; Tretinoin | 1989 |
Etretinate pharmacokinetics in chronic renal failure. A preliminary study in psoriasis patients.
Chronic renal failure (CRF) interferes with the catabolism of retinol and is frequently associated with hypervitaminosis A. The effect of CRF on the plasma levels of etretinate (Tigason, Tegison), an aromatic retinoid, was therefore studied in 4 patients who were given the drug as part of a maintenance antipsoriatic regimen. The concentrations of the parent compound and its main metabolites (etretin and isoetretin) were monitored for 24 h after receiving a routine dose of the drug. In comparison with 4 non-CRF patients receiving similar maintenance doses of etretinate, although the CRF patients had higher peak levels of the parent compound (p less than 0.01), the levels of the metabolites were similar or lower. The plasma half-lives for all compounds were approximately the same in each group, indicating that the catabolism of the drug was not affected by CRF. However, elevated etretinate concentrations may increase the drug accumulation in fat tissues and thereby prolong the time required for final elimination of the drug. Topics: Acitretin; Etretinate; Humans; Kidney Failure, Chronic; Kidney Function Tests; Psoriasis; Tretinoin | 1987 |
Severe vasculitis during isotretinoin therapy.
Topics: Adolescent; Biopsy; Granulomatosis with Polyangiitis; Humans; Isotretinoin; Kidney; Kidney Failure, Chronic; Lung; Male; Tretinoin; Vasculitis | 1987 |
Plasma vitamin A in haemodialysis patients.
Different high performance liquid chromatographic systems were applied to the investigation of vitamin A metabolism in subjects undergoing haemodialysis. Plasma levels of retinol, retinyl esters and retinoic acid were measured. There was a significant elevation of plasma retinol and dialysis failed to normalise this level. No correlation with plasma concentrations of creatinine or urea was found. No differences in retinyl ester and retinoic acid levels were observed between healthy subjects and haemodialysis patients. These results suggest that retinol accumulation is not caused by a deficiency in its oxidative metabolism. Topics: Adult; Chromatography, High Pressure Liquid; Creatinine; Esters; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Tretinoin; Urea; Vitamin A | 1981 |
Keratotic papules in chronic renal disease.
Three patients with renal disease had hyperkeratotic follicular and parafollicular lesions on the extremities. Since all of these patients had renal disease, we hypothesize that an abnormality in the renal-calcium-vitamin D-parathyroid chain allows the pathologic accumulation of keratinous debris that characterizes Kyrle's disease. As with other diseases with abnormal keratin generation, the retinoids, specifically topical tretinoin, ameliorate this condition. Despite controversial reports about poor results with tretinoin therapy, our patients have had good results without recurrences and tolerated tretinoin well. Topics: Adult; Darier Disease; Humans; Kidney Failure, Chronic; Male; Tretinoin | 1981 |